Rifampicin (RIF) is an important first-line antibiotic for the treatment of mycobacterial infections including leprosy. It is a bactericidal antibiotic that inhibits the bacterial RNA polymerase. Rifampicin resistance is therefore a valuable surrogate marker for drug resistance in leprosy. The aim of the study was to identify mutation in the rpoB (Rifampicin), folP (Dapsone) and gyrA (Ofloxacin) genes by molecular methods in leprosy patients from the TLM hospitals in India. Among 215 cases, we detected seven cases of primary drug resistance to rifampicin.
BT - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases C1 -http://www.ncbi.nlm.nih.gov/pubmed/26314915?dopt=Abstract
DO - 10.1016/j.cmi.2015.08.004 J2 - Clin. Microbiol. Infect. LA - eng N2 -Rifampicin (RIF) is an important first-line antibiotic for the treatment of mycobacterial infections including leprosy. It is a bactericidal antibiotic that inhibits the bacterial RNA polymerase. Rifampicin resistance is therefore a valuable surrogate marker for drug resistance in leprosy. The aim of the study was to identify mutation in the rpoB (Rifampicin), folP (Dapsone) and gyrA (Ofloxacin) genes by molecular methods in leprosy patients from the TLM hospitals in India. Among 215 cases, we detected seven cases of primary drug resistance to rifampicin.
PY - 2015 T2 - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases TI - Emergence of primary drug resistance to rifampicin in Mycobacterium leprae strains from leprosy patients in India. SN - 1469-0691 ER -